Therapeutic options for metastatic breast cancer

Patrick G. Morris, Heather L. McArthur, Clifford A. Hudis

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.

Original languageEnglish (US)
Pages (from-to)967-981
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Issue number6
StatePublished - Apr 2009
Externally publishedYes


  • Breast cancer
  • Chemotherapy
  • Endocrine therapy
  • Metastatic disease
  • Targeted agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Therapeutic options for metastatic breast cancer'. Together they form a unique fingerprint.

Cite this